Overview

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Status:
COMPLETED
Trial end date:
2025-06-12
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: * To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. * To evaluate the pharmacokinetics of oral olanzapine tablets following multiple dose administration. * To monitor the safety and tolerability of multiple doses of oral olanzapine tablets given in the study.
Phase:
PHASE1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Treatments:
Olanzapine